drugset / Trial / NCT02886702

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702

Phase 3 Completed 855 enrolled Fougera Pharmaceuticals Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Timeline

Start
2016-09-19
Primary completion
2017-08-02
Completion
2017-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.05 % Topical

Indications